Cargando…

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells

A critical problem in leukemia as well as other cancer therapies is the development of chemotherapeutic drug-resistance. We have developed models of hematopoietic drug resistance that are based on expression of dominant-negative TP53 [TP53 (DN)] or constitutively-active MEK1 [MEK1(CA)] oncogenes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abrams, Stephen L., Ruvolo, Peter P., Ruvolo, Vivian R., Ligresti, Giovanni, Martelli, Alberto M., Cocco, Lucio, Ratti, Stefano, Tafuri, Agostino, Steelman, Linda S., Candido, Saverio, Libra, Massimo, McCubrey, James A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652725/ https://www.ncbi.nlm.nih.gov/pubmed/29100331 http://dx.doi.org/10.18632/oncotarget.20408

Ejemplares similares

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression
por: Steelman, Linda S., et al.
Publicado: (2017)

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals
por: Abrams, Stephen L., et al.
Publicado: (2021)

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
por: Duda, Przemysław, et al.
Publicado: (2020)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

Cancer therapy and treatments during COVID-19 era
por: Akula, Shaw M., et al.
Publicado: (2020)

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity
por: Chappell, William H., et al.
Publicado: (2012)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties
por: McCubrey, James A., et al.
Publicado: (2022)

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
por: McCubrey, James A., et al.
Publicado: (2022)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
por: McCubrey, James A., et al.
Publicado: (2017)

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
por: McCubrey, James A., et al.
Publicado: (2016)

TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer
por: Akula, Shaw M., et al.
Publicado: (2020)

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
por: Taylor, Jackson R., et al.
Publicado: (2011)

MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma
por: Falzone, Luca, et al.
Publicado: (2016)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer
por: Candido, Saverio, et al.
Publicado: (2014)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

GSK-3 as potential target for therapeutic intervention in cancer
por: McCubrey, James A., et al.
Publicado: (2014)

Advances in Targeting Signal Transduction Pathways
por: McCubrey, James A., et al.
Publicado: (2012)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Cutaneous melanoma: From pathogenesis to therapy (Review)
por: Leonardi, Giulia C., et al.
Publicado: (2018)

Bioinformatic analysis of the LCN2–SLC22A17–MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment
por: Candido, Saverio, et al.
Publicado: (2022)

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
por: McCubrey, J A, et al.
Publicado: (2014)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer
por: Falzone, Luca, et al.
Publicado: (2016)

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
por: Davis, Nicole M., et al.
Publicado: (2014)

Emerging targeted therapies for melanoma treatment (Review)
por: RUSSO, ANGELA, et al.
Publicado: (2014)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets
por: Vivarelli, Silvia, et al.
Publicado: (2020)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
por: Bevelacqua, Valentina, et al.
Publicado: (2012)

Lamin B1 Accumulation’s Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes
por: Ratti, Stefano, et al.
Publicado: (2021)

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia
por: Iacovelli, Stefano, et al.
Publicado: (2015)

Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases
por: Fazio, Antonietta, et al.
Publicado: (2020)

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
por: Cervello, Melchiorre, et al.
Publicado: (2013)

A novel DAG-dependent mechanism links PKCa and Cyclin B1 regulating cell cycle progression
por: Poli, Alessandro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qpmkve94fuq98bcf3m6hpcntec